Canary's role is not 100% clear yet, as they only have a letter of intent. So all the cards aren't on the table yet. But my understanding is they make a specific type of cancer testing product. It identifies if a person has a certain type of cancer. It's my belief that Regen will modify this testing product to detect the types of cancers that their tumor-reducting medication can treat. That way they can market the whole package to hospitals (identification testing and subsequent treatment). But of course, I could be wrong.
As far as BRG goes, again it's not clear. But I tend to believe they were hired to provide a valuation of their I.P. in case Regen received buyout offers. It's a huge bargaining tool to have such a valuation. That way nothing is a "guess" or an "exaggeration." They are literally using industry facts, stats and trends in their estimate of Regen's worth. A potential buyer can't really argue with that. This also allows Koos to identify if a licensing deal or buyout offer is unfair in any way.
JMO.
News 
Market Data 
Discover 
